NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. [PDF]
Cancer Med, 2022 TRK fusions are rare but targetable mutations which occur across a wide variety of cancer types. We report the prevalence of approximately 0.7% for NTRK‐positive colorectal cancer (CRC) by genetically profiling 2519 colonic and rectal tumors.
Wang H +7 more
europepmc +2 more sources
Precision oncology: the intention-to-treat analysis fallacy. [PDF]
, 2020 It has recently been suggested that precision oncology studies should be reanalysed using the intention-to-treat (ITT) methodology developed for randomized controlled clinical trials.
Kato, Shumei +3 more
core +1 more source
Primary and Metastatic Melanoma With NTRK Fusions [PDF]
American Journal of Surgical Pathology, 2018 A number of oncogenic driver mutations have been identified in melanocytic nevi and melanoma, but translocations also play a role in tumorigenesis and provide potential therapeutic targets for malignant lesions. Various translocations, such as those involving the anaplastic lymphoma kinase (ALK), neurotrophic tropomyosin receptor kinase 1 (NTRK1), and ...
Cecilia, Lezcano +4 more
openaire +2 more sources
Pleomorphic xanthoastrocytoma with NTRK fusion presenting as spontaneous intracranial hemorrhage-case report and literature review. [PDF]
Front PediatrBackground Pleomorphic xanthoastrocytoma (PXA) is a rare brain tumor that accounts for
Wu Y +8 more
europepmc +2 more sources
JTO Clinical and Research Reports, 2023 The NTRK genes encode the TRK proteins. NTRK fusions lead to constitutively active, ligand-independent downstream signaling. NTRK fusions are implicated in up to 1% of all solid tumors and 0.2% of NSCLC.
Mary C. Boulanger, MD +4 more
doaj +1 more source
healthbook TIMES. Oncology Hematology, 2021 In May 2020, larotrectinib (Vitrakvi^®^) was approved as the first tumor-agnostic agent in Switzerland for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (*NTRK*) gene fusion.
Holger Moch +9 more
doaj +2 more sources
Identificación de genes de fusión NTRK. Experiencia en México
Gaceta Mexicana de Oncología, 2023 Objetivo: Evaluar la prevalencia de fusiones TRK en pacientes con cáncer en México. Material y métodos: En un estudio de tipo canasta, se determinó la presencia de genes de fusión NTRK, mediante inmunohistoquímica y secuenciación de nueva generación, en ...
Leticia Bornstein-Quevedo +4 more
doaj +1 more source
A Case of NTRK Fusion Corpus Sarcoma With Pseudobiphasic Growth Pattern and Literature Review. [PDF]
Int J Gynecol PatholThe incidence of neurotrophic tyrosine kinase receptor (NTRK) fusion uterine sarcoma is extremely low, and reports have been mostly focused on cases localized to the cervix. So far, only 4 cases have been reported of the uterine corpus. In this study, we
Zhang XY +7 more
europepmc +2 more sources
Single-Institution Experience of Larotrectinib Therapy for Patients With NTRK Fusion-Positive Thyroid Carcinoma. [PDF]
J Endocr SocContext The real world efficacy and tolerabiltiy of NTRK inhibitor larotrectinib has not yet been reported in the literature although trial data has shown promising results.
Elghawy O +5 more
europepmc +2 more sources
Evaluation of NTRK Gene Fusion by Five Different Platforms in Triple-Negative Breast Carcinoma
Frontiers in Molecular Biosciences, 2021 Triple-negative breast carcinoma (TNBC) is an aggressive disease that has a poor prognosis since it lacks effective treatment methods. Neurotrophic tyrosine receptor kinase (NTRK) fusion genes are excellent candidates for targeted RTK inhibitor therapies
Shafei Wu +5 more
doaj +1 more source